Giovanni Nigita
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
171
Citations
2,793
Est. group size
~25
Recurring co-author estimate
Active years
20
Publishing since 2007
Giovanni Nigita studies small molecules called microRNAs and other non-coding RNAs, focusing on how chemical modifications and editing of these molecules contribute to cancer development and treatment resistance, such as in melanoma, lung cancer, and leukemia. His work also explores using these RNA molecules found in blood or other body fluids (liquid biopsies) as markers to help diagnose cancer or predict patient outcomes, sometimes combined with computational and machine-learning methods.
Publication output has grown substantially over the past decade, rising from single digits in 2017-2019 to a peak of 47 in 2023, with continued strong activity through 2024-2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Improving mortality prediction in critically ill cancer patients with a multidimensional machine learning model
medRxiv · 2026
- A multi-omics approach to identify the impact of miR-411ed on NSCLC TKI resistance
bioRxiv (Cold Spring Harbor Laboratory) · 2026
- SorenKK/FGTD: FGTD - v 1.0.0 - Zenodo
Open MIND · 2026
- SorenKK/FGTD: FGTD - v 1.0.0 - Zenodo
Zenodo (CERN European Organization for Nuclear Research) · 2026
- Improving mortality prediction in critically ill cancer patients with a multidimensional machine learning model
Intensive Care Medicine Experimental · 2026
- Improving mortality prediction in critically ill cancer patients with a multidimensional machine learning model
UNC Libraries · 2026
- International society of liquid biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumors
The Journal of Liquid Biopsy · 2025
- Pleural Fluid Extracellular Vesicle MicroRNA as a Prognostic Indicator in Malignant Pleural Effusion
American Journal of Respiratory and Critical Care Medicine · 2025
- Pleural Fluid Extracellular microRNA-141-3p Can Differentiate Cytology-negative Malignant From Non-malignant Pleural Effusion
American Journal of Respiratory and Critical Care Medicine · 2025
- The MITF/mir-579-3p regulatory axis dictates BRAF-mutated melanoma cell fate in response to MAPK inhibitors
Cell Death and Disease · 2024
- ncRNA Editing: Functional Characterization and Computational Resources
Methods in molecular biology · 2024
- Editorial: RNA modifications and epitranscriptomics, Volume II
Frontiers in Genetics · 2023
- MITF/miR-579-3p novel regulatory axis controls BRAF-mutated melanoma decision between cell senescence or progression upon exposure to MAPK inhibitors.
Zenodo (CERN European Organization for Nuclear Research) · 2023
- MITF/miR-579-3p novel regulatory axis controls BRAF-mutated melanoma decision between cell senescence or progression upon exposure to MAPK inhibitors.
Zenodo (CERN European Organization for Nuclear Research) · 2023
- The Epitranscriptome in miRNAs: Crosstalk, Detection, and Function in Cancer
Genes · 2022
- Cancer Research×17
- Proceedings of the National Academy of Sciences×9
- bioRxiv (Cold Spring Harbor Laboratory)×9
- Zenodo (CERN European Organization for Nuclear Research)×6
- The Journal of Liquid Biopsy×4
- Paolo Fadda
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Rosario Distefano
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Pierluigi Gasparini
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Gian Luca Rampioni Vinciguerra
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Jia Wang
Biochemistry, Genetics and Molecular Biology · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile